# Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT03746652** · PHASE2 · UNKNOWN · sponsor: **Hellenic Society of Hematology** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab, Ixazomib, Dexamethasone

## Key facts

- **NCT ID:** NCT03746652
- **Lead sponsor:** Hellenic Society of Hematology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-11-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746652, "Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03746652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*